Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海凯宝药业股份有限公司主要从事清热解毒类中成药痰热清注射液的研发、生产和销售的企业,公司生产产品主要包括:小容量注射剂、片剂、硬胶囊剂、颗粒剂、合剂、糖浆剂、口服液、中药提取等,以及部分农副产品收购,以及少量生产盐酸吡格列酮片、卡托普利缓释片、多索茶碱胶囊等产品.公司产品痰热清注射液是国家专利产品,国家中药二类新药,痰热清注射液质量稳定、疗效显著,入选上海市抗"非典"重点新产品,被国家列入"人禽流感用药目录"、"防止流感储备药品"、防治手足口病临床治疗药物,2009年9月痰热清注射液被列为甲型H1N1流感诊疗治疗药物和甲型H1N1流感重症与危重症辩证治疗方案治疗药物.并具有清热解毒、化痰解痉的作用,对抗病毒有独特的疗效,对肺炎链球菌、嗜血流感杆菌、乙型溶血性链球菌、黄金色葡萄球菌有抑制作用.公司先后多次荣获殊荣:2005-2006年度价格诚信自律先进单位称号、最具成长性科技型中小企业100强荣誉、2006技术工作先进单位称号、信用等级AAA级企业荣誉、药品质量诚信建设示范企业称号上海市高新技术企业称号。
Main Business 清热解毒类中成药痰热清注射液的研发、生产和销售。
Legal Representative 穆竟伟
Top Executives
董事长：穆竟伟
董事：周迎宾,王国明,刘建中,任立旺,荆树中
独立董事：马洪,李珍妮,叶祖光
Top 5 Shareholder
Shareholder name Nature Holding Date
穆竟伟限售股+流通A股16.06%30/09/2024
张艳琪流通A股15.37%30/09/2024
新乡市凯谊实业有限公司流通A股7.50%30/09/2024
香港中央结算有限公司流通A股0.92%30/09/2024
穆竟男流通A股0.79%30/09/2024
Company Secretary 任立旺
Solicitors 通力律师事务所
Auditors 立信会计师事务所有限公司
Tel No 021-37572069
Fax No 021-37572069
Website www.xykb.com
Email kbyydmb@126.com
Company Address
Register: 上海市工业综合开发区程普路88号
Office: 上海市工业综合开发区程普路88号
Listing Date 08/01/2010
Shares Capital
Shares Capital: 1,046,000,000
Total A Share: 1,046,000,000
Listed A Share: 916,926,226
Non-tradable A Share: 129,073,774
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.314
DPS(RMB)* ¥ 0.100
NBV Per Share(RMB)* ¥ 3.854
Market Capitalization(RMB) 5.868B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.